List of news
26/04/2013 Guerbet at ESPR 2013
Marriott Hotel, Budapest, Hungary, June 3-7 2013
23/04/2013 2013 first-quarter revenue
Year's start impacted by the good performance in 2012 H2
21/03/2013 USA: FDA Approves Dotarem®
FDA Approves Dotarem® (gadoterate meglumine), first macrocyclic and ionic gadolinium-based contrast agent in USA
06/03/2013 2012 annual results
Sustained growth mainly from gains in the second half
15/02/2013 USA: Medical Imaging Drugs Advisory Committee Recommends Approval of Guerbet NDA for Dotarem
Guerbet announced that the Medical Imaging Drugs Advisory Committee to US Food and Drug Administration (FDA) has voted unanimously by votes of 17 to 0 to recommend that FDA approve the New Drug Application (NDA) for Dotarem® (gadoterate meglumine) for adults, and for pediatric use for children...
08/02/2013 Revenue 2012
Sustained growth mainly driven by gains in the second half.
18/01/2013 Guerbet at ECR 2013
Vienna, Austria Center Vienna, – March 7-11, 2013 (Thursday to Monday)